IMR Press / FBE / Volume 7 / Issue 2 / DOI: 10.2741/E735

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Tumour-associated macrophage polarisation and re-education with immunotherapy
Show Less
1 St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences & Medicine, King’s College London; NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospital and King’s College London, Guy’s Hospital, London, UK
2 Research Oncology, Division of Cancer Studies, Faculty of Life Sciences & Medicine, King’s College London, Guy’s Hospital, London, UK

*Author to whom correspondence should be addressed.

Academic Editor: George John Kontoghiorghes

Front. Biosci. (Elite Ed) 2015, 7(2), 334–351;
Published: 1 January 2015

Monocytes/macrophages constitute important contributors of cancer-associated inflammation. Through their plasticity and capacity to become polarised by tumours towards less activatory and more immunosuppressive (M2) phenotypes, tumour-associated macrophages (TAM) are thought to support tumour progression. Orchestrated by T helper 2 (Th2)-biased stimuli, macrophage recruitment, activation and polarisation in tumour microenvironments is associated with poorer clinical outcomes. Their key roles in supporting tumour progression and their capacity for plasticity have focused targeted and immunotherapeutic strategies to counteract macrophage pro-tumourigenic activities and to re-ignite their tumour-cytotoxic power. Therapeutic approaches include blockade of macrophage recruitment into tumours, suppression of TAM survival, re-polarisation towards an M1-like phenotype and antibody therapies to enhance TAM anti-tumoural activities. Future immunotherapeutic directions may include monoclonal antibodies with enhanced effector functions. Antibodies of different classes, including those of the IgE class, shown to restrict tumour growth by harnessing monocyte/macrophage cytotoxic properties in pre-clinical cancer models, may synergise or re-educate these potent immune sentinels to destroy rather than support tumours. Opportunities for monitoring monocyte/macrophage polarisation or activatory signatures in patients may inform clinical management.

tumour immunotherapy
monoclonal antibodies
tumour microenvironment
M1 macrophages
M2 macrophages
Th1/Th2 responses
Back to top